Vivos Therapeutics Announces Binding Debt-to-Equity Exchange Agreement with Streeterville Capital
Key Highlights for Investors
- Debt-to-Equity Exchange of Up to \$4.5 Million: Vivos Therapeutics, Inc. (NASDAQ: VVOS) has entered into a binding agreement with its senior secured lender, Streeterville Capital, LLC, to exchange up to \$4.5 million of outstanding debt into a combination of perpetual, nonconvertible preferred stock and common stock.
- Temporary Suspension of Debt Repayments and Security Sales: Streeterville has committed to suspend any calls for repayments of its debt for 90 days and to halt any sales of company securities for 60 days after the exchange becomes effective.
- Support for Nasdaq Listing: The transaction is intended to bolster Vivos’ stockholders’ equity, which is a key factor in maintaining its Nasdaq listing and addressing compliance with listing standards.
- Recent Transformative Acquisition: In June 2025, Vivos completed the acquisition of The Sleep Center of Nevada (SCN), the state’s largest operator of medical sleep centers, significantly enhancing its business model and revenue potential.
- Contingency on Equity Financing: The debt-to-equity exchange is contingent upon Vivos completing one or more qualifying equity financings on terms acceptable to the company.
Details and Implications for Shareholders
The agreement with Streeterville Capital marks a significant step for Vivos Therapeutics as it seeks to strengthen its balance sheet and secure its listing on the Nasdaq. The conversion of debt into equity, if successfully executed, will reduce the company’s debt service obligations—improving cash flows and liquidity—at a critical time for the company.
Notably, Streeterville’s suspension of debt repayment calls and the sale of company securities for 90 and 60 days, respectively, provides a window of financial flexibility. This breathing room may allow Vivos to pursue strategic opportunities and stabilize operations post-acquisition.
The company’s acquisition of SCN in June 2025, supported by both debt and new equity investments, was transformative. It marked Vivos’ first major move into sleep testing centers and associated medical sleep practices, expanding its business model from medical devices and healthcare services to direct patient care and diagnostics.
However, the debt-to-equity exchange is not guaranteed. It is dependent on the company’s ability to secure additional equity financing, the terms of which remain to be finalized. There are risks that such financing may not materialize, that the conditions for the exchange may not be met, or that the exchange may not ultimately occur.
The company’s management also cautions that, even if the transactions are completed, there is no assurance that the company will fully realize the intended benefits, including increased stockholders’ equity and improved cash flows. Failure to execute these plans could jeopardize the company’s Nasdaq listing and future operations.
About Vivos Therapeutics
Vivos Therapeutics is a Colorado-based medical technology and healthcare services company specializing in innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA). The company’s FDA-cleared CARE (Complete Airway Repositioning and Expansion) devices are unique in the market, being the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate-to-severe OSA in children.
The company’s approach, known as The Vivos Method, is proprietary, nonsurgical, noninvasive, and nonpharmaceutical. Vivos aims to address the root causes of OSA, differentiating itself from legacy treatments like CPAP devices.
Risks and Forward-Looking Statements
- Vivos may not be able to raise the required new equity in a timely or sufficient manner, which could nullify the debt-to-equity exchange agreement.
- Even if the transactions are consummated, the company may not be able to realize the expected benefits.
- There are risks related to the implementation of strategies to increase revenue, the effectiveness of Vivos products, regulatory scrutiny, adverse publicity, and the ability to secure future financing.
- Market conditions and compliance with Nasdaq listing requirements remain ongoing concerns for the company.
Investor Relations Contact
Jennifer Hauser
Investor Relations Contact
[email protected]
Disclaimer: This article contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from expectations. Investors should review all risk factors disclosed in Vivos’ SEC filings and consult their financial advisors before making investment decisions. This article does not constitute an offer to sell or a solicitation of an offer to buy any securities.
